Apremilast, by Celgene [109], is the second approved PDE4 inhibitor in 2014 and was marketed for the treatment of psoriatic arthritis and moderate to severe plaque psoriasis that do not respond to topical glucocorticoid therapy. Here, PDE4A is linked to psoriatic arthritis.